Friday 6 November 2026 Export SYRE’s income statement to Excel — free account

Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022.

EPS: −624.8%
Free cash flow: −108.8%

Quarter to September 2026, against a year earlier

102.07 5.48 +5.67%

Follow SYRE

Alert me

Market cap: $9.2B
P/E: 0.0×
Fwd P/E: −4.8×
Dividend yield: —
F-score: 3/9
Altman Z: −3.82
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Spyre Therapeutics, Inc. (SYRE) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Spyre Therapeutics, Inc. (SYRE) trades at a P/B ratio of 9.5×. Over the past ten years it has ranged from 0.0× (June 2024) to 15.3× (June 2026); the current reading is higher than 97% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/SYRE/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Spyre Therapeutics, Inc. P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/SYRE/metrics/pb-ratio">Spyre Therapeutics, Inc. (SYRE) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2023	0.0×	—
FY2022	0.7×	(81.01%)
FY2021	3.7×	60.84%
FY2018	2.3×	43.06%
FY2017	1.6×	127.49%
FY2016	0.7×	—
FY2015	0.0×	—

Period	P/B ratio	Change
Dec 2023	0.0×	—
Jun 2023	0.0×	—
Mar 2023	0.8×	15.01%
Dec 2022	0.7×	(3.71%)
19 more quarters	Free account

Against its own ten years

Low 0.0× High 15.3×

Ten-year median 2.6×

Current reading's percentile 96

Company	P/B ratio
CYTK Cytokinetics, Incorporated compare	n/m
IBRX ImmunityBio, Inc. compare	n/m
KRYS Krystal Biotech, Inc. compare	6.2×
SYRE Spyre Therapeutics, Inc.	9.5×
PTGX Protagonist Therapeutics, Inc. compare	10.6×
CAI Caris Life Sciences,�Inc. compare	12.7×
TGTX TG Therapeutics, Inc. compare	13.6×
TWST Twist Bioscience Corporation compare	17.1×
MDGL Madrigal Pharmaceuticals, Inc. compare	18.7×
Biotechnology industry median	2.0×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Spyre Therapeutics, Inc. (SYRE) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on SYRE

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on SYRE

Stockrow Weekly